These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 5045616)

  • 1. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 2. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 4. Dose-related alterations in metabolism of levodopa: possible mechanism for hypotensive effect.
    Kochar MS; Itskovitz HD; Sasse EA; Baker JD; Doumas BT
    J Clin Pharmacol; 1974; 14(8):448-54. PubMed ID: 4851433
    [No Abstract]   [Full Text] [Related]  

  • 5. Peripheral aromatic L-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism of L-2- 14 C-dopa.
    Bianchine JR; Messiha FS; Hsu TH
    Clin Pharmacol Ther; 1972; 13(4):584-94. PubMed ID: 5042372
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease.
    Bianchine JR; Calimlim LR; Morgan JP; Dujuvne CA; Lasagna L
    Ann N Y Acad Sci; 1971 Jul; 179():126-40. PubMed ID: 5285373
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 9. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of antacid administration on the absorption and metabolism of levodopa.
    Leon AS; Spiegel HE
    J Clin Pharmacol New Drugs; 1972 Jul; 12(7):263-7. PubMed ID: 4483533
    [No Abstract]   [Full Text] [Related]  

  • 11. Catecholamine metabolism during oral administration of levodopa.
    Hinterberger H; Andrews CJ
    Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays.
    Morgan JP; Bianchine JR; Spiegel HE; Rivera-Calimlim L; Hersey RM
    Arch Neurol; 1971 Jul; 25(1):39-44. PubMed ID: 5146410
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 15. [Qualitative analysis of the main urinary metabolites of dopamine, epinephrine and norepinephrine by gas chromatography].
    Bègue RJ; Bazerolle O; Desgres J; Lallemant C; Padieu P
    Pathol Biol (Paris); 1971; 19(15):719-25. PubMed ID: 4942503
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism.
    Peaston MJ; Bianchine JR; Messiha FS
    Life Sci; 1973 Aug; 13(3):237-46. PubMed ID: 4750920
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of methyldopa on the excretion of catecholamines in patients with extrapyramidal disorders.
    Metzel A; Holldorf A; Umbach W
    Confin Neurol; 1967; 29(2):78-80. PubMed ID: 5591949
    [No Abstract]   [Full Text] [Related]  

  • 19. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolism of 3,4-dihydroxyphenylalanine (L-dopa) in human subjects.
    Goodall M; Alton H
    Biochem Pharmacol; 1972 Sep; 21(17):2401-8. PubMed ID: 4647074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.